Diabetes & Vascular Disease Research is a leading academic journal dedicated to advancing the understanding and treatment of cardiovascular and metabolic diseases, particularly diabetes. Published by SAGE Publications Ltd in the United Kingdom, this journal serves as a key resource for researchers, clinicians, and students seeking to explore the intricate relationship between diabetes and vascular health. With an impressive Impact Factor and ranked in the Q2 quartile in prominent categories such as Cardiology, Endocrinology, and Internal Medicine, the journal provides a platform for high-quality, peer-reviewed research. Covering a broad range of topics from pathophysiology to therapeutic innovations, Diabetes & Vascular Disease Research plays a vital role in shaping contemporary discourse in the field. With contributions from leading experts and a commitment to disseminating valuable findings, this journal is a must-read for anyone involved in the fight against vascular complications arising from diabetes.

Vascular Medicine is a premier academic journal for researchers and practitioners in the field of cardiovascular health, published by SAGE Publications Ltd. With an ISSN of 1358-863X and E-ISSN 1477-0377, this esteemed journal has been at the forefront of publishing quality research since its inception in 1992, with convergence extending to 2024. Ranked in the Q2 category for both Cardiology and Cardiovascular Medicine as well as for miscellaneous Medicine in 2023, it is recognized for its significant contributions to advancing knowledge and clinical practice within these domains. Its Scopus ranking situates it at #91 out of 387 in the field, reflecting its high impact and the relevance of its published research, which is crucial for addressing the challenges in vascular health today. Although it is not an open-access journal, Vascular Medicine remains dedicated to disseminating vital findings that bridge the gap between research and clinical application, making it an essential resource for medical researchers, healthcare professionals, and students alike.

CURRENT CARDIOLOGY REVIEWS, an esteemed journal published by BENTHAM SCIENCE PUBL LTD, is a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1573-403X and E-ISSN of 1875-6557, this journal presents comprehensive reviews that contribute significantly to the advancement of scientific knowledge and clinical practices in cardiology. Operating with open access options, CURRENT CARDIOLOGY REVIEWS is dedicated to bridging the gap between research and practice, thereby encouraging interdisciplinary collaboration and knowledge sharing. The journal has been instrumental in disseminating high-impact findings, consistently maintaining a Q2 category ranking in both Cardiology and Cardiovascular Medicine, as well as within the miscellaneous categories of Medicine, highlighting its relevance and respect in the academic community. Researchers, practitioners, and students alike will find valuable insights into contemporary cardiovascular issues, practices, and innovations that promote better patient outcomes. Based in the United Arab Emirates, CURRENT CARDIOLOGY REVIEWS encourages global contributions and reflects the latest advancements up to the year 2024, solidifying its role as an essential publication for those engaged in the quest for excellence in cardiovascular health.

International Heart Journal, published by INT HEART JOURNAL ASSOC, serves as a pivotal platform for research and discourse in the fields of cardiology and cardiovascular medicine. With its ISSN 1349-2365 and E-ISSN 1349-3299, this esteemed journal is based in Japan and is located at the University of Tokyo, Graduate School of Medicine, Department of Cardiovascular Medicine. Since its inception in 2005, International Heart Journal has blossomed into a respected publication with an impact factor that signifies its growing relevance, ranking in the Q3 category of both cardiology and miscellaneous medicine as of 2023. This journal not only disseminates vital research findings but also fosters collaboration among researchers and healthcare professionals. Notable for its Open Access options, it ensures the availability of its content to a broader audience, thereby enhancing knowledge transfer and innovation in cardiovascular care. With an ongoing commitment to improve clinical practice and patient outcomes, the journal continues to be an essential resource for those dedicated to advancing the understanding of heart health and disease.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Artery Research is an esteemed open access journal published by BMC in the United Kingdom, dedicated to advancing the field of vascular biology and cardiovascular medicine. Since its inception in 2006 and transitioning to an open access format in 2019, the journal has become a pivotal platform for disseminating high-quality research on arterial health, pathology, and the latest clinical advancements. With an impactful focus on anatomy, cardiology, and physiology, Artery Research holds a notable reputation within the global research community, ranked in the Q3 and Q4 category quartiles in its respective fields and reflected in its Scopus ranks. The journal aims to foster collaborations and discussions among researchers and practitioners by providing an accessible avenue for publishing pivotal findings and insights. As it continues to evolve through 2024 and beyond, Artery Research remains committed to enriching cardiovascular research and driving innovations toward better health outcomes.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

INFLAMMATION RESEARCH, published by SPRINGER BASEL AG, serves as a pivotal journal in the fields of Immunology and Pharmacology, with notable rankings of Q2 in Immunology and Q1 in Pharmacology as of 2023. With an ISSN of 1023-3830 and an E-ISSN of 1420-908X, this esteemed journal, located in Basel, Switzerland, has been at the forefront of advancing our understanding of inflammatory processes since its inception in 1995. Covering research trends and breakthroughs until 2024, it significantly contributes to both the theoretical frameworks and practical applications within its discipline, boasting a strong Scopus ranking of #40/313 in Pharmacology and #56/236 in Immunology, placing it in the top percentiles for its field. Although it does not offer Open Access options, the journal remains an invaluable resource for researchers, professionals, and students committed to unraveling the complexities of inflammation and its implications in health and disease.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.